Murli Krishna Pharma Pvt Ltd (MKPPL) is set to showcase its latest advancements in drug delivery systems (DDs) making a significant mark at WHX Lagos 2025, scheduled from June 2 to 4, 2025 at the Landmark Centre in Lagos, Nigeria.
This event is a major platform for healthcare innovation, and MKPPL’s participation in this event shows its commitment to transforming global healthcare, especially in regions like Africa where access to advanced medicines is more than necessary.
Who is Murli Krishna Pharma Pvt Ltd?
Murli Krishna Pharma Pvt Ltd is a 20-year-old leading Indian pharmaceutical company, known for its commitment on innovation, quality, and patient-centric solutions.
Under the leadership of Dr. Satya Vadlamani (MD), MKPPL has built a reputation by specializing in Novel Drug Delivery Systems (NDDS), including nanoparticles, nano encapsulations, and liposomes.
They excel in producing oral solid dosages, oral liquids, and external preparations.
The company’s R&D center is approved by the Department of Scientific and Industrial Research (DSIR), Government of India, highlighting its focus on innovative research.
The company has successfully undergone audits from major pharmaceutical companies like Sanofi, STADA, and Pfizer, showcasing their commitment to quality and regulatory compliance.
With a global reach spanning over 78 countries and serving more than 200 customers worldwide.
MKPPL’s vision is to revolutionize the pharmaceutical industry through cutting-edge nano encapsulation and novel drug delivery systems, aiming for a turnover of USD 200 million by 2026.
Their mission is to transform healthcare through relentless innovation, solidifying their position as a leader in Novel Drug Delivery Systems (NDDS) and expanding their development of Intelligent Pharmaceutical Solutions (IPS).
What Makes MKPPL’s Drug Delivery Systems Unique?
MKPPL is known in the pharma industry for its use of cutting-edge technologies such as nano encapsulation and liposomal drug delivery.
These advanced systems are designed to improve the effectiveness and safety of medicines by ensuring that drugs are delivered precisely where they are needed in the body, at the right time and in the right amount.
Some of their notable innovations include:
Pellets and Micro-Pellets: These are tiny, controlled-release forms of medication that can be used in capsules, tablets, or suspensions, making dosing more accurate and improving patient compliance.
Nanosuspensions: By reducing drug particles to the nanoscale, MKPPL enhances the solubility and bioavailability of medicines, allowing for better absorption and faster action.
Liposomal Encapsulation: This technology uses lipid-based carriers to deliver drugs, which can help reduce side effects and increase the effectiveness of treatments.
Transdermal Lotions: MKPPL has developed innovative lotions for conditions like anemia, offering a non-invasive alternative to traditional treatments and supporting initiatives like India’s “Anemia Mukt Bharat”.
Commitment to Quality and Compliance
MKPPL’s is committed to quality and compliance. Its state-of-the-art manufacturing facilities adhere to strict international standards such as EU-GMP, WHO-GMP, and Indian FDA guidelines. Besides, its plants have been audited and approved by major international regulatory agencies, ensuring that every product meets the highest standards for safety and quality.
MKPPL’s dedicated R&D center is managed by experienced scientists who continuously work on developing new, effective and improved drug delivery solutions.
Focus on Africa and WHX Lagos 2025
Limited access to quality, affordable and effective medicines is one of the biggest challenges faced by Africa.
Under the leadership of Dr. Satya Vadlamani, MKPPL recognizes this critical need for an innovative healthcare solution in the region.
Hence, by participating in the much-awaited WHX Lagos 2025, MKPPL aims the following:
Introduce Affordable Medicines: Leveraging cost-effective manufacturing, MKPPL can provide high-quality drugs at prices accessible to a wider population.
Showcase Advanced Drug Delivery:
The company’s novel technologies, such as nano and liposomal systems, can improve treatment outcomes and patient centric.
Build Local Partnerships: MKPPL seeks to work together with African governments, healthcare providers, and NGOs to ensure effective distribution and adoption of its products.
Support Capacity Building: By training local healthcare professionals and exploring the possibility of local manufacturing, MKPPL aims to foster self-reliance and sustainable development in the African healthcare sector.
Why WHX Lagos 2025 Matters?
WHX is one of the largest and most influential healthcare events in West Africa with 7,000 attendees, 500+ global exhibitors, and 100+ influential speakers, making it a central hub for networking, learning, and business opportunities in the healthcare sector.
The event will showcase innovations across 8 major healthcare product categories, namely medical devices, laboratory diagnostics, digital health care, pharmaceuticals, and wellness solutions. This is a platform for enhanced collaboration and knowledge sharing.
Murli Krishna Pharma Pvt Ltd, under the leadership of Dr. Satya Vadlamani, MD, seeks to demonstrate its leadership in Drug Delivery Technology and its commitment to improving healthcare outcomes globally, especially with emerging markets like Africa.
Participation for Transformative Impact
Murli Krishna Pharma Pvt Ltd’s participation at WHX Lagos 2025 is not just about business growth, rather it’s the guided vision to make a transformative impact on global healthcare, especially Africa.
By combining innovation, quality, and a patient-first approach, MKPPL is setting new benchmarks in the pharmaceutical industry globally.
MKPPL’s focus on advanced drug delivery systems promises safer, more effective, and more accessible treatments for patients worldwide, particularly in regions where they are needed most.
As MKPPL continues to push the boundaries of pharmaceutical science, its presence at WHX Lagos 2025 will be a testament to how Indian innovation can help solve global healthcare challenges and improve lives across continents.
FAQs [Frequently Asked Questions]
Where is Murli Krishna Pharma Pvt Ltd based?
Murli Krishna Pharma Pvt Ltd is based in Ranjangaon, Taluka Shirur, Pune, Maharashtra, India.
Who is the founder of Murli Krishna Pharma Pvt Ltd?
Murli Krishna Pharma Pvt Ltd was founded by Dr. Satya Vadlamani and Dr. Vijay K. Shastri in 2004.
Who is Dr. Satya Vadlamani?
Dr. Satya Vadlamani is the Managing Director (MD) of Murli Krishna Pharma Pvt Ltd, with over 30 years of experience in the pharmaceutical industry.
She is recognized for her business acumen, leadership and innovation in drug delivery systems and has received several accolades in her field.
Is Murli Krishna Pharma Pvt Ltd a recognized company?
Yes, Murli Krishna Pharma Pvt Ltd is a well-recognized company, approved by regulatory bodies like the European Union, WHO, and Indian FDA, and has cleared audits from major global pharmaceutical companies.
What are the certifications of Murli Krishna Pharma Pvt Ltd?
The company holds EU-GMP, WHO-GMP, and Indian FDA certifications, and its facilities are approved for manufacturing by international authorities such as the European Union and Jordanian FDA.
Are the healthcare solutions of Murli Krishna Pharma Pvt Ltd effective?
Yes, Murli Krishna Pharma Pvt Ltd provides a range of effective drug delivery solutions, using advanced technologies like nano and liposomal encapsulation to improve the quality and effectiveness of medical care.
What does Murli Krishna Pharma Pvt Ltd specialize in?
The company specializes in novel drug delivery systems, including pre-finished formulation intermediates, finished dosage forms, pellets, micro-pellets, nano emulsions, and transdermal lotions.
